Cirrhosis: Let s get moving!

Similar documents
(Mal)nutrition and liverdisease

Treatment of sarcopenia: latest developments. Dr Miles D Witham Clinical Reader in Ageing and Health University of Dundee.

The place of bariatric surgery in NASH: can we extend the indications? - No

Causes of Liver Disease in US

Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate

Viral hepatitis and Hepatocellular Carcinoma

Prescription Fitness. Robert M. Pepper, DO, FAAFP. ACOFP 55th Annual Convention & Scientific Seminars

HCV TREATMENT PRE- AND POST TRANSPLANTATION

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Jong Young Choi, M.D.

MAXIMAL AEROBIC POWER (VO 2max /VO 2peak ) Application to Training and Performance

ESPEN Congress Madrid 2018

Frailty Assessment: Simplifying the Complex

Endpoints And Indications For The Older Population

Cardiac Rehabilitation Program for LVAD Patients. Dr Katherine Fan Consultant Cardiologist Grantham Hospital, Hong Kong SAR

FRAILTY SYNDROME. dr. Rose Dinda Martini, Sp.PD, K-Ger

Cases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease

3/6/2017. Objectives. Prehabilitation Training the Frail. I have no financial relationships with commercial interests to disclose.

Biological Correlates of Frailty in Older Heart Failure Patients

Frailty conundrums: dilemmas and unsolved conceptual issues.

Patterns of abnormal LFTs and their differential diagnosis

Worldwide Causes of HCC

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Cardiac Rehabilitation for Heart Failure Patients. Jia Shen MD, MPH Assistant Professor of Medicine UC San Diego Health System

Patterns of abnormal LFTs and their differential diagnosis

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu

Life After SVR for Cirrhotic HCV

Worldwide Causes of HCC

Screening for HCCwho,

Does Viral Cure Prevent HCC Development

Research in Hepatology What is hot and what is not!

What is frailty and why it is important

Frailty: from Academic Definition to Clinical Applicability

HCV care after cure. This program is supported by educational grants from

Studiedag Geriatrie, Leuven Bewegen als geneesmiddel. Sarcopenie

Scope

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Modulate the prevention stategy according to the level of frailty. Prof Leocadio Rodríguez Mañas Hospital Universitario de Getafe

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma: Epidemiology and Screening

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Beta-blockers in cirrhosis: Cons

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

SUBMAXIMAL EXERCISE TESTING: ADVANTAGES AND WEAKNESS IN PERFORMANCE ASSESSMENT IN CARDIAC REHABILITATION

Surveillance for Hepatocellular Carcinoma

Malnutrition in advanced CKD

Learning Objectives. After attending this presentation, participants will be able to:

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

The Deconditioned Elderly Patient: Have We Been Getting it Wrong? By: Ernest Roy PT, DPT

Experience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona

King s College Hospital NHS Foundation Trust. Acute on Chronic Liver Failure: Practical management outside the tertiary centre.

Hepatocellular Carcinoma: Diagnosis and Management

Frailty, Sarcopenia and Outcomes after Emergency Surgery Admissions Across Wessex

Hepatocellular Carcinoma (HCC)

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

Hepatology for the Nonhepatologist

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

HCC: Is it an oncological disease? - No

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

SportsMed Update. Volume 8 (7) 4: 2008

Challenge: the elderly patient with cancer The physical therapists perspective

Paul Martin MD FACG. University of Miami

Chapter 26: Exercise Assessment in Special Populations

Liver resection for HCC

Update on Frailty. Stephanie Studenski Longitudinal Studies Section Intramural Research Program National Institute on Aging

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

Alcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD

GI bleeding in chronic liver disease

Approach to Abnormal Liver Tests

Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation

Molecular signature for management of hepatocellular carcinoma

FRAILTY AND COGNITION IN THE ASSESSMENT OF VASCULAR SUGERY PATIENTS WHY WHY DISCLOSURES. INDIVIDUAL None. INSTITUTIONAL Cook, Inc

Hepatocellular carcinoma

Management of HCV in Decompensated Liver Disease

Protein Requirements for Optimal Health in Older Adults: Current Recommendations and New Evidence

Interventions to improve physical function and prevent adverse events in cirrhosis

Optimizing the Lung Transplant Candidate through Exercise Training. Lisa Wickerson BScPT, MSc Canadian Respiratory Conference April 25, 2014

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Nutrition Management of End- Stage Liver Failure

A study of serum ferritin as a prognostic marker in patients with decompensated liver disease

3/25/2010. Age-adjusted incidence rates for coronary heart disease according to body mass index and waist circumference tertiles

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

Nutrition in the critically ill elderly (geriatric) patient CHRISTINA NIEUWOUDT RD(SA) SASPEN/CCSSA CONGRESS 2017

Role of Aerobic Exercise in Post-polio Syndrome. Dr. Jülide Öncü,MD İstanbul Sisli Etfal Teaching Hospital

Frailty in Older Mexican Americans

Arresting Frailty and Sarcopenia in Cirrhosis: Future Prospects

CANCER AND EXERCISE: IMPROVING PHYSICAL FUNCTION AND CARDIOPULMONARY HEALTH DURING AND AFTER TREATMENT

Stick or twist management options in hepatitis C

REVIEW ARTICLE. Andres Duarte-Rojo, 1 Astrid Ruiz-Margain, 3 Aldo J. Monta~no-Loza, 4 Ricardo U. Macıas-Rodrıguez, 3 Arny Ferrando, 2 and W.

Hands on Sports Therapy KNOWLEDGE REVIEW QUESTIONS 2004 Thomson Learning It can help to shape a basic fitness training programme

Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018

Transcription:

Cirrhosis: Let s get moving! Puneeta Tandon Cirrhosis Care Clinic, University of Alberta ADDS 2014 Objectives Physical Deconditioning in Cirrhosis What is it? Why does it happen? Clinical Relevance Potential therapies Exercise Nutrition Cirrhosis is associated with a high disease burden 12 th leading cause of death in the US 1 million clinic visits and 300,000 hospitalizations per year Sicker patients on the transplant list Davis GL et al. Gastroenterol 2010 1

Goals of care Identify and treat modifiable prognostic factors in an attempt to maintain health and optimize outcomes Etiology based treatment (HCV, HBV, Etoh, Hemochromatosis, AIH) Guideline based management to reduce acute hits to the liver (Variceal bleed, Infection, HCC) Optimize functional status so patients are less vulnerable when exposed to a stressor TAKE HOME POINT #1 Patients with cirrhosis are deconditioned Etiology of this deconditioning is multifactorial Exercise capacity 101 Peak exercise capacity the maximum ability of the CV system to deliver O 2 to exercising skeletal muscle and of the muscle to extract O 2 from the blood VO 2 = (SV x HR) x (CaO 2 CvO 2 ) in ml/min VO 2 normalized for body weight 3.5 ml/kg/min (resting seated O 2 uptake) Equivalent to 1 MET Albouaini K et al. Heart 2007 2

Cardiopulmonary exercise testing Albouaini K et al. Heart 2007 Peak VO 2 across age & fitness continuum Maximal or Peak VO 2 (ml/kg/min) Hagan et al. Med Sc Sports Exerc.1981; Jones A. Int J Sports Sci & Coaching.2006; Wilson & Tanaka. AJP Heart. 2000; Kitzman et al. JAMA. 2002. Activities of daily living as a percent of peak VO 2 in Decompensated Cirrhosis Percent peak VO 2 2.5 3.0 3.0 3.3 4.3 5.3 5.5 MET data from Ainsworth et al. MSSE, 2011 3

Multiple factors impact the VO 2 in cirrhosis Lemyze M et al. Digestive and Liver Disease 2012 TAKE HOME POINT #1 Patients with cirrhosis are deconditioned Etiology of this deconditioning is multifactorial TAKE HOME POINT #2 VO 2 and it s determinants / correlates are strong independent predictors of poor outcome 4

6213 men referred for treadmill exercise testing. After adjustment, the peak exercise capacity was the strongest predictor of death, each 1 MET increase in capacity conferring a 12% improvement in survival Myers J et al. NEJM 2002 The VO 2 also has excellent prognostic value in cirrhosis N=135 to 399 Independent of MELD in the prediction of mortality pre transplantation Independent predictor of post transplant mortality, hospital and ICU length of stay Epstein SK et al. Liver Transplantation 2004 Dharancy S et al. Transplantation 2008 Prentis JM et al. Liver Transplantation 2012 Bernal W et al. Liver Transplantation 2013 Neviere R et al. AJT 2013 Components/correlates of VO 2 also have prognostic value Lemyze M et al. Digestive and Liver Disease 2012 5

Muscle mass loss: MAMC N=1053 MAMC <5 th % in 38% M, 8% F P=0.03 Merli M Hepatology 1996 Muscle mass loss: L3 Skeletal Muscle Index N=142 Sarcopenia in 54% M, 21% F p = 0.04 Tandon, Myers et al. Liver Transpl 2012 Montano Loza et al. Clin Gastro Hep 2012 Limitations with considering size alone Goodpaster BH Gerentology2006 Cruz Jentoft A et al. Age and Ageing 2010 6

Hand grip strength Prospective, cross sectional study of 50 patients with cirrhosis. 88% CP A Abnormal hand grip predicted a composite endpoint of ascites, HE, SBP, HRS at 1 year of follow up 66% versus 12% of patients Alvares DaSilva MR, Nutrition 2005 Six minute walk distance predicts mortality in liver transplant candidates ~50% increase in survival for every 100 meter increase in the 6MWD < 2 miles/hour VO 2 of 9 ml/kg/min Carey EJ Liver Transplantation 2010 Frailty Multidimensional model Slowness 4 m gait speed Cognitive impairment MOCA Depressed mood HADS Weakness Handgrip FRIED FRAILTY Weight loss >5 lbs or 10% BW over 1y Low physical activity PASE Exhaustion CES D Frail: 3 criteria Moreley JE et al. JAMDA 2013 7

Update at AASLD 2013 502 patients No correlation with age, gender, BMI, etiology of liver disease Independent of MELD in predicting mortality (HR = 2.7, p=0.02) Sonnenday C et al. Hepatology 2010, 2013 (abstracts) TAKE HOME POINT #2 VO 2 and it s determinants / correlates are strong independent predictors of poor outcome TAKE HOME POINT #3 Exercise + Nutritional Therapy is a promising intervention for MODIFYING exercise capacity and its determinants/correlates 8

Exercise effects in healthy controls Increases SV, lowers HR, improves large arterial compliance A vo 2 content difference Increases muscle mass and quality, capillary density, mitochondrial number and oxidative capacity Improves QOL, mood and reduces fatigue, beneficial metabolic effects Albouaini K et al. Heart 2007 Exercise in cirrhosis Limited data evaluating impact on muscle mass or exercise capacity 5 patients examined at baseline and after 6 and 12 weeks of an exercise program. VO 2 max increased by 19% and 29% 4 patients underwent a 4 5 week exercise program. 2 increased their VO 2 peak (by 21% and 27%) and 2 had no change Ritland S et al. Scand J Gastroenterol 1983 Campillo B et al. J Hepatol 1990 Concerns about exercise in cirrhosis 1 On placebo On BB On placebo On BB Bandi J et al. Hepatol 1998 9

Exercise trial: Pilot RCT 19 cirrhotics (74% Child Pugh A), 79% men, mean age 58, mean MELD 10 Randomized to 8 weeks of cycle ergometer exercise training 3 days a week (at 60 80% of baseline peak VO 2 ) versus usual care All patients received regular follow up with a dietician and had variceal proph if needed Zenith L et al. Clin Gastroenterol Hepatol (in press) Exercise trial: Pilot RCT Primary outcome Peak VO 2 Secondary outcomes Ultrasound measured quadriceps thickness Thigh circumference 6 minute walk distance Fatigue Self perceived health status (VAS) Adverse outcomes Zenith L et al. Clin Gastroenterol Hepatol (in press) Zenith L et al. CDDW 2013 Results 1 Zenith L et al. Clin Gastroenterol Hepatol (in press) 10

Improvement in physiological age 90 80 70 60 50 40 30 20 10 0 Age 77 77 67 57 Baseline True Age Baseline End of Study End of Study Physiological age Physiological Age Physiological Age Control Exercise Baseline True Age Baseline Physiological age End of Study Physiological Age Control End of Study Physiological Age Exercise Zenith L et al. Clin Gastroenterol Hepatol (in press) Results 1 Zenith L et al. Clin Gastroenterol Hepatol (in press) Results 2 Zenith L et al. Clin Gastroenterol Hepatol (in press) 11

Conclusions Impaired Exercise Tolerance in Cirrhosis Common and associated with poor outcomes Potentially modifiable Nutrition + Exercise therapy require further study Likely to have different benefits at different CP classes. May be particularly beneficial with NAFLD Improving pre and post transplant outcomes, functionality, QOL, fatigue Point of futility? 12